Nuclera is driven by the mission to better human health by increasing accessibility to proteins. We are committed to providing rapid access to high-quality, soluble, active proteins at the benchtop allowing researchers to accelerate their protein projects, enabling faster success. Using Nuclera’s eProtein Discovery™ system scientists can automate construct screening to inform off-platform protein scale up, delivering reliable protein in-hand (µg-mg amounts) in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
Location: United Kingdom, England, Cambridge
Employees: 51-200
Total raised: $100.5M
Founded date: 2013
Investors 2
| Date | Name | Website |
| - | Verve Vent... | verve.vc |
| 18.02.2022 | Amadeus Ca... | amadeuscap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.07.2022 | Series B | $58M | Verve Vent... |
| 03.02.2022 | Series B | $42.5M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 28.09.2022 | Innovative 3D printing-enabled strain sensor unlocks real-ti... | Researchers at Stanford University have used 3D printing to develop a strain sensor that enables the... | 3dprinting... |
| 14.07.2022 | Nuclera raises another $15.5M towards launch of gene protein... | Biotechnology start-up Nuclera has attracted a further $15.5 million in Series B funding, taking its... | 3dprinting... |
| 03.02.2022 | Nuclera raises $42.5M in first close of Series B for desktop... | Nuclera raises $42.5M in first close of Series B for desktop protein printer 03-02-2022 Nuclera, a... | cambridgen... |
| 03.02.2022 | Nuclera raises $42.5M in first close of Series B for desktop... | Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, announces... | cambridgen... |
| 02.02.2022 | M&G : invests $10 million into Nuclera as it expands its... | News release M&G invests $10 million into Nuclera as it expands its technology range for resea... | marketscre... |
| 02.02.2022 | UK biotech startup ropes in $42.5 million to create 3D prote... | Biotech company developing cutting-edge benchtop protein printing technologies, Nuclera has raised $... | tech.eu/20... |
| 02.02.2022 | Nuclera Raises $42.5M in First Close of Series B Financing | Nuclera, a Cambridge, UK- and Boston, Massachusetts-based biotech company developing benchtop protei... | finsmes.co... |
| 02.02.2022 | Nuclera raises $42.5M towards launch of new protein 3D print... | Insiders and analysts have made their predictions on the 3D printing trends to watch out for. Find o... | 3dprinting... |
| 23.05.2020 | Mike Kamdar, The Future Of DNA Writing, And The Business Of ... | With a new way to write DNA, Mike Kamdar and his team at Molecular Assemblies are poised to disrupt ... | forbes.com... |
| - | UK biotech startup ropes in $42.5 million to create 3D prote... | Biotech company developing cutting-edge benchtop protein printing technologies, Nuclera has raised $... | tech.eu/20... |
Show more